Bellecapital International Ltd. Grows Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Bellecapital International Ltd. grew its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMOGet Rating) by 19.2% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 6,337 shares of the medical research company’s stock after buying an additional 1,020 shares during the period. Bellecapital International Ltd.’s holdings in Thermo Fisher Scientific were worth $3,214,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Bornite Capital Management LP grew its position in shares of Thermo Fisher Scientific by 50.0% in the first quarter. Bornite Capital Management LP now owns 30,000 shares of the medical research company’s stock valued at $17,719,000 after purchasing an additional 10,000 shares during the period. Fairfield Bush & CO. grew its position in shares of Thermo Fisher Scientific by 1.2% in the first quarter. Fairfield Bush & CO. now owns 2,928 shares of the medical research company’s stock valued at $1,729,000 after purchasing an additional 36 shares during the period. Loomis Sayles & Co. L P grew its position in Thermo Fisher Scientific by 563.5% during the first quarter. Loomis Sayles & Co. L P now owns 19,844 shares of the medical research company’s stock valued at $11,721,000 after acquiring an additional 16,853 shares during the period. Covestor Ltd grew its position in Thermo Fisher Scientific by 60.5% during the first quarter. Covestor Ltd now owns 321 shares of the medical research company’s stock valued at $190,000 after acquiring an additional 121 shares during the period. Finally, Merit Financial Group LLC grew its position in Thermo Fisher Scientific by 3.6% during the first quarter. Merit Financial Group LLC now owns 669 shares of the medical research company’s stock valued at $395,000 after acquiring an additional 23 shares during the period. Hedge funds and other institutional investors own 85.92% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have issued reports on TMO. Wells Fargo & Company lowered their price target on Thermo Fisher Scientific from $525.00 to $505.00 and set an “underweight” rating for the company in a research report on Tuesday, January 3rd. Robert W. Baird lowered their price target on Thermo Fisher Scientific from $711.00 to $696.00 and set an “outperform” rating for the company in a research report on Thursday, October 27th. Barclays boosted their price target on Thermo Fisher Scientific from $570.00 to $630.00 and gave the company an “overweight” rating in a research report on Tuesday. Deutsche Bank Aktiengesellschaft began coverage on Thermo Fisher Scientific in a research note on Tuesday, December 13th. They set a “buy” rating and a $620.00 price objective on the stock. Finally, Benchmark cut Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Thursday, October 27th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $633.30.

Thermo Fisher Scientific Stock Down 1.3 %

NYSE TMO traded down $7.26 on Wednesday, hitting $573.46. 86,728 shares of the stock traded hands, compared to its average volume of 1,931,608. The stock has a 50-day moving average of $556.73 and a 200 day moving average of $547.95. Thermo Fisher Scientific Inc. has a twelve month low of $475.77 and a twelve month high of $618.35. The company has a market capitalization of $224.91 billion, a P/E ratio of 32.64, a price-to-earnings-growth ratio of 2.11 and a beta of 0.83. The company has a current ratio of 1.74, a quick ratio of 1.22 and a debt-to-equity ratio of 0.65.

Thermo Fisher Scientific (NYSE:TMOGet Rating) last announced its quarterly earnings data on Wednesday, October 26th. The medical research company reported $5.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.78 by $0.30. The firm had revenue of $10.68 billion for the quarter, compared to analysts’ expectations of $9.86 billion. Thermo Fisher Scientific had a return on equity of 22.97% and a net margin of 15.92%. As a group, analysts expect that Thermo Fisher Scientific Inc. will post 23.04 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, January 16th. Stockholders of record on Thursday, December 15th were issued a dividend of $0.30 per share. This represents a $1.20 annualized dividend and a dividend yield of 0.21%. The ex-dividend date of this dividend was Wednesday, December 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 6.75%.

Thermo Fisher Scientific announced that its board has authorized a share repurchase program on Thursday, November 10th that permits the company to repurchase $4.00 billion in shares. This repurchase authorization permits the medical research company to purchase up to 2% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s board of directors believes its stock is undervalued.

Insider Activity

In related news, EVP Gianluca Pettiti sold 4,975 shares of the stock in a transaction that occurred on Tuesday, December 13th. The stock was sold at an average price of $576.84, for a total value of $2,869,779.00. Following the completion of the transaction, the executive vice president now directly owns 16,450 shares of the company’s stock, valued at approximately $9,489,018. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Monday, October 31st. The stock was sold at an average price of $509.97, for a total value of $5,099,700.00. Following the completion of the transaction, the chief executive officer now directly owns 178,005 shares of the company’s stock, valued at approximately $90,777,209.85. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Gianluca Pettiti sold 4,975 shares of the stock in a transaction that occurred on Tuesday, December 13th. The stock was sold at an average price of $576.84, for a total value of $2,869,779.00. Following the completion of the transaction, the executive vice president now directly owns 16,450 shares of the company’s stock, valued at $9,489,018. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 31,475 shares of company stock valued at $16,073,443. 0.43% of the stock is currently owned by insiders.

Thermo Fisher Scientific Profile

(Get Rating)

Thermo Fisher Scientific, Inc engages in the provision of analytical instruments, equipment, reagents and consumables, software, and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Read More

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMOGet Rating).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.